Engineers Gate Manager LP Protagonist Therapeutics, Inc Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $613,121 - $865,232	-24,863 Reduced 66.18%	12,707 $440,000
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $545,795 - $805,293	25,048 Added 200.03%	37,570 $1.09 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $187,314 - $312,502	-13,332 Reduced 51.57%	12,522 $287,000
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $431,244 - $611,705	25,854 New	25,854 $431,000
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $63,709 - $149,995	-5,910 Reduced 38.91%	9,278 $213,000
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $111,783 - $169,649	15,188 New	15,188 $165,000
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $320,382 - $1.16 Million	-45,380 Reduced 79.95%	11,383 $90,000
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.32 Million - $2.05 Million	56,763 New	56,763 $1.34 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $60,994 - $234,039	-4,710 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $120,434 - $211,384	4,710 New	4,710 $211,000
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $247,830 - $405,884	-13,030 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $240,924 - $327,443	13,030 New	13,030 $263,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.92B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.